Group One Trading
ABUS icon

Group One Trading’s Arbutus Biopharma ABUS Stock Holding History

Group One Trading’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$229K Sell
50,843
-7,573
-13% -$33.1K ﹤0.01% 4003
2025
Q4 		$281K Buy
58,416
+12,622
+28% +$56.8K ﹤0.01% 4065
2025
Q3 		$208K Buy
45,794
+19,219
+72% +$70.6K ﹤0.01% 4630
2025
Q2 		$82.1K Sell
26,575
-14,500
-35% -$48.1K ﹤0.01% 5147
2025
Q1 		$143K Sell
41,075
-11,123
-21% -$37.1K ﹤0.01% 4296
2024
Q4 		$171K Sell
52,198
-7,361
-12% -$27.1K ﹤0.01% 4067
2024
Q3 		$229K Buy
59,559
+33,368
+127% +$128K ﹤0.01% 3490
2024
Q2 		$80.9K Sell
26,191
-39,776
-60% -$119K ﹤0.01% 4131
2024
Q1 		$170K Buy
65,967
+58,655
+802% +$152K ﹤0.01% 3701
2023
Q4 		$18.3K Buy
+7,312
New +$14.3K ﹤0.01% 5814
2022
Q4 		– Sell
-6,112
Closed -$14.6K – 7137
2022
Q3 		$12K Sell
6,112
-7,723
-56% -$18.2K ﹤0.01% 6366
2022
Q2 		$37K Sell
13,835
-171,946
-93% -$440K ﹤0.01% 5806
2022
Q1 		$554K Sell
185,781
-172,741
-48% -$529K ﹤0.01% 3700
2021
Q4 		$1.4M Buy
358,522
+106,297
+42% +$413K ﹤0.01% 2985
2021
Q3 		$1.08M Buy
252,225
+179,394
+246% +$598K ﹤0.01% 3329
2021
Q2 		$221K Sell
72,831
-51,758
-42% -$160K ﹤0.01% 5142
2021
Q1 		$415K Sell
124,589
-204,092
-62% -$788K ﹤0.01% 4258
2020
Q4 		$1.17M Buy
328,681
+255,120
+347% +$893K ﹤0.01% 2511
2020
Q3 		$230K Buy
+73,561
New +$224K ﹤0.01% 3539
2020
Q2 		– Sell
-5,476
Closed -$8.96K – 5721
2020
Q1 		$6K Buy
+5,476
New +$14.8K ﹤0.01% 4715
2019
Q4 		– Sell
-3,140
Closed -$5.08K – 5039
2019
Q3 		$5K Sell
3,140
-1,402
-31% -$2.42K ﹤0.01% 4751
2019
Q2 		$9K Buy
+4,542
New +$11.6K ﹤0.01% 4438
2019
Q1 		– Sell
-1,781
Closed -$6.84K – 4718
2018
Q4 		$7K Buy
+1,781
New +$8.77K ﹤0.01% 4374
2017
Q4 		– Sell
-19,830
Closed -$116K – 4781
2017
Q3 		$123K Buy
19,830
+6,281
+46% +$26.9K ﹤0.01% 3097
2017
Q2 		$49K Buy
13,549
+6,090
+82% +$21K ﹤0.01% 3517
2017
Q1 		$24K Sell
7,459
-37,418
-83% -$104K ﹤0.01% 3793
2016
Q4 		$110K Buy
44,877
+21,398
+91% +$62.3K ﹤0.01% 2788
2016
Q3 		$81K Buy
23,479
+11,105
+90% +$43.4K ﹤0.01% 3065
2016
Q2 		$43K Sell
12,374
-5,082
-29% -$21.5K ﹤0.01% 3390
2016
Q1 		$72K Sell
17,456
-2,797
-14% -$9.99K ﹤0.01% 3040
2015
Q4 		$90K Sell
20,253
-58,300
-74% -$320K ﹤0.01% 3038
2015
Q3 		$478K Buy
78,553
+10,125
+15% +$89.8K 0.01% 1817
2015
Q2 		$812K Buy
+68,428
New +$1.04M 0.01% 1386
2015
Q1 		– Sell
-26,397
Closed -$541K – 4704
2014
Q4 		$400K Buy
+26,397
New +$456K 0.01% 1725
2014
Q3 		– Sell
-21,264
Closed -$347K – 5080
2014
Q2 		$278K Sell
21,264
-18,721
-47% -$265K ﹤0.01% 2117
2014
Q1 		$859K Buy
+39,985
New +$718K 0.01% 1205

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Group One Trading's ABUS Position: Q1 2026 in Review

Group One Trading reduced its Arbutus Biopharma (ABUS) stake by 13% in Q1 2026, selling an estimated $33.1K and leaving 50,843 shares worth $229K. The position accounts for ﹤0.01% of the portfolio, ranked #4003.

Group One Trading first reported a position in ABUS in Q1 2014 and has held it in 36 quarters since. The position peaked at $1.4M in Q4 2021. 167 funds tracked by Wall St. Rank hold ABUS as of Q1 2026.

  • Group One Trading held 50,843 shares of Arbutus Biopharma worth $229K as of Q1 2026.
  • Group One Trading sold 7,573 Arbutus Biopharma shares in Q1 2026, an estimated $33.1K.
  • Arbutus Biopharma made up ﹤0.01% of Group One Trading's portfolio in Q1 2026, its #4003 holding.
  • Group One Trading first reported a position in Arbutus Biopharma in Q1 2014 and has held it in 36 quarters since.
  • Group One Trading's Arbutus Biopharma position peaked at $1.4M in Q4 2021.
  • 167 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.